Loading clinical trials...

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

NCT00523341•Amgen

View on ClinicalTrials.gov

Summary

The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who previously received denosumab or placebo, respectively.

Eligibility

Age

60 - 94 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Subjects must sign the informed consent before any study specific procedures are performed and agree to receive denosumab 60 mg subcutaneous injection every 6 months
•Subjects must not have discontinued investigational product during the 20030216 study and must have attended the 20030216 study month 36 visit
•Subjects must be re-consented prior to (or at) the 24 month visit for participation beyond month 24.

Exclusion Criteria

•Permanently non-ambulatory subjects (use of an assistive device eg, cane, walker, etc. is permitted)
•Missed 2 or more investigational product doses during the 20030216 study
•Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures
•Developed sensitivity to mammalian cell derived drug products during the 20030216 study
•Unable to tolerate calcium supplementation during the last 6 months of participation in the 20030216 study (between the month 30 and month 36 20030216 study visits)
•Currently receiving any investigational product other than denosumab or having received any investigational product during the 20030216 study
•Current use of the following osteoporosis agents: bisphosphonates, calcitonin, fluoride, parathyroid hormone, selective estrogen receptor modulators, systemic oral or transdermal estrogen (except vaginal preparations and estrogen creams which are acceptable), strontium, or tibolone
•For bone biopsy sub-study subjects only: known or suspected sensitivity or contraindication to tetracycline derivatives

Key Dates

Start Date

August 7, 2007

Primary Completion Date

July 19, 2015

Completion Date

July 19, 2015

Last Updated

November 7, 2022

Enrollment

4,550

ACTUAL participants

Conditions

OsteopeniaOsteoporosis

Interventions

Denosumab

BIOLOGICAL

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

NCT06731608

OsteoporosisLower Limb Fracture

View study

RECRUITING

Smart Wearable Device (gaitQ): Walk Better Project

NCT05913219

Parkinson DiseaseStroke+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Inclusion Criteria

Exclusion Criteria

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Smart Wearable Device (gaitQ): Walk Better Project

Step-down Therapy After Long-term Osteoporosis Treatment

Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning

Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship

Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device